Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 4
1987 1
1989 1
1990 1
1991 3
1992 3
1993 1
1995 5
1996 3
1998 2
1999 1
2000 4
2001 5
2002 1
2003 1
2004 4
2005 3
2006 2
2007 4
2008 4
2009 5
2010 10
2011 9
2012 8
2013 10
2014 2
2015 8
2016 6
2017 2
2018 5
2019 4
2020 1
2021 5
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Results by year

Filters applied: . Clear all
Page 1
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
de Blank PMK, Gross AM, Akshintala S, Blakeley JO, Bollag G, Cannon A, Dombi E, Fangusaro J, Gelb BD, Hargrave D, Kim A, Klesse LJ, Loh M, Martin S, Moertel C, Packer R, Payne JM, Rauen KA, Rios JJ, Robison N, Schorry EK, Shannon K, Stevenson DA, Stieglitz E, Ullrich NJ, Walsh KS, Weiss BD, Wolters PL, Yohay K, Yohe ME, Widemann BC, Fisher MJ. de Blank PMK, et al. Among authors: bollag g. Neuro Oncol. 2022 Nov 2;24(11):1845-1856. doi: 10.1093/neuonc/noac165. Neuro Oncol. 2022. PMID: 35788692 Free PMC article. Review.
Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model.
Spangenberg E, Severson PL, Hohsfield LA, Crapser J, Zhang J, Burton EA, Zhang Y, Spevak W, Lin J, Phan NY, Habets G, Rymar A, Tsang G, Walters J, Nespi M, Singh P, Broome S, Ibrahim P, Zhang C, Bollag G, West BL, Green KN. Spangenberg E, et al. Among authors: bollag g. Nat Commun. 2019 Aug 21;10(1):3758. doi: 10.1038/s41467-019-11674-z. Nat Commun. 2019. PMID: 31434879 Free PMC article.
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. Wilhelm SM, et al. Among authors: bollag g. Cancer Res. 2004 Oct 1;64(19):7099-109. doi: 10.1158/0008-5472.CAN-04-1443. Cancer Res. 2004. PMID: 15466206
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich TMP, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa MSZ, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz PE, Burton EA, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin AD. McNamara B, et al. Among authors: bollag g. Gynecol Oncol. 2023 May;172:65-71. doi: 10.1016/j.ygyno.2023.03.009. Epub 2023 Mar 21. Gynecol Oncol. 2023. PMID: 36958197
Phosphodiesterase-4 as a potential drug target.
Zhang KY, Ibrahim PN, Gillette S, Bollag G. Zhang KY, et al. Among authors: bollag g. Expert Opin Ther Targets. 2005 Dec;9(6):1283-305. doi: 10.1517/14728222.9.6.1283. Expert Opin Ther Targets. 2005. PMID: 16300476 Review.
Regulators and effectors of ras proteins.
Bollag G, McCormick F. Bollag G, et al. Annu Rev Cell Biol. 1991;7:601-32. doi: 10.1146/annurev.cb.07.110191.003125. Annu Rev Cell Biol. 1991. PMID: 1667084 Review. No abstract available.
Vemurafenib: the first drug approved for BRAF-mutant cancer.
Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P. Bollag G, et al. Nat Rev Drug Discov. 2012 Nov;11(11):873-86. doi: 10.1038/nrd3847. Epub 2012 Oct 12. Nat Rev Drug Discov. 2012. PMID: 23060265 Review.
Triple Therapy to Outwit the BRAF Oncogene.
Zhang C, Bollag G. Zhang C, et al. Among authors: bollag g. Cancer Discov. 2021 Jul;11(7):1620-1622. doi: 10.1158/2159-8290.CD-21-0378. Cancer Discov. 2021. PMID: 34284995
Hyperactive Ras in developmental disorders and cancer.
Schubbert S, Shannon K, Bollag G. Schubbert S, et al. Among authors: bollag g. Nat Rev Cancer. 2007 Apr;7(4):295-308. doi: 10.1038/nrc2109. Nat Rev Cancer. 2007. PMID: 17384584 Review.
118 results